SABR for Renal Cell Carcinoma Offers Excellent Outcomes 12 Jan 2018 Stereotactic ablative radiotherapy (SABR) for patients with primary renal cell carcinoma (RCC) is well tolerated and is associated with excellent local oncologic control,... Read More